Physician profile
Eric Tamrazian
NPI 1881078251
$4,420.61
in general payments reported to CMS, 2019-2025
22 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $615 · 2024: $1,675 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,420.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,284.12 | 2023-2025 | Zilbrysq, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $783.12 | 2023-2025 | |
| Abbvie INC. | $657.17 | 2023-2025 | Botox |
| Pfizer INC. | $616.61 | 2023-2025 | |
| Lilly USA, LLC | $149.59 | 2024 | Emgality, Kisunla, Amyvid |
| Medtronic, INC. | $146.67 | 2023 | Percept PC Brainsense |
| Amgen INC. | $122.17 | 2025 | |
| Alexion Pharmaceuticals, INC. | $95.45 | 2025 | Ultomiris |
| Lundbeck LLC | $86.91 | 2024 | Vyepti |
| Genentech USA, INC. | $70.00 | 2024 | Ocrevus, Ocrevus Zunovo |
| Tanabe Pharma America, INC. | $57.32 | 2024-2025 | Radicava |
| Argenx US, INC. | $52.70 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $51.94 | 2024 | |
| Cycle Pharmaceuticals INC | $32.09 | 2025 | Bafiertam, Tascenso Odt |
| Axsome Therapeutics, INC. | $29.04 | 2023 | Sunosi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $28.28 | 2023 | Cala Trio |
| Teva Pharmaceuticals USA, INC. | $28.01 | 2025 | Austedo Xr |
| Microtransponder, INC. | $26.76 | 2024 | |
| Biogen, INC. | $26.55 | 2024 | Leqembi |
| Sk Life Science, INC. | $26.29 | 2025 | |
| Amneal Pharmaceuticals LLC | $25.41 | 2023 | Rytary |
| Abbott Laboratories | $24.41 | 2024 | Infinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tamrazian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.